Interleukin-17 and kidney allograft outcome

Transplant Proc. 2009 Jun;41(5):1562-4. doi: 10.1016/j.transproceed.2009.01.092.

Abstract

Acute rejection episodes (ARE) are important complications that involve the interplay between mechanisms that maintain graft tolerance and promote rejection. The proinflammatory cytokine interleukin-17 (IL-17) has been implicated in many conditions in humans and mice. In kidney transplant patients, the evaluation IL-17 levels has been performed in only a few patients. We performed a cross-sectional study correlating quantitative IL-17 levels and clinical outcomes.

Patients and methods: We studied 19 specimens from biopsies performed in patients (n = 19) who received isolated kidney grafts. ARE signs were present in 9 (47%) patients who provide specimens; whereas, 10 (53%) others showed no signs of rejection. Eighteen healthy control sample IL-17 underwent measurement, all of which were performed by an enzyme-linked immunosorbent assay method. We assessed other factors, such as the recipients demographic data, cold ischemia time, HLA mismatches, time elapsed from transplantation to the biopsy, posttransplantation status, antibody panel, donor type, and immunosuppressive treatment.

Results: IL-17 levels were clearly increased among samples derived from patients with ongoing rejection (125.7 +/- 27.06 pg/mL) in contrast, to the nonrejection group, (30 +/- 13.32 pg/mL) (P < .05). Healthy controls showed no detectable IL-17 levels.

Conclusions: These findings suggested that IL-17 was important in the pathophysiology of acute kidney rejection.

MeSH terms

  • Adult
  • Animals
  • Biomarkers / blood*
  • Biopsy
  • Female
  • Graft Rejection / blood*
  • Graft Rejection / immunology
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Interleukin-17 / blood*
  • Male
  • Mice
  • Middle Aged
  • Reference Values

Substances

  • Biomarkers
  • Immunosuppressive Agents
  • Interleukin-17